Cobenfy (anozivikanwawo seKarXT), musanganiswa wemishonga xanomeline uye trospium chloride, yakaongororwa kuti inoshanda pakurapa schizophrenia uye yakabvumidzwa neFDA seantipsychotic munaGunyana 2024.1. Izvi, zvisinei, rudzi rutsva rwakakwana rwekurapa schizophrenia sezvo mishonga yose yapfuura inopikisa dopamine receptor (inonzi maitiro antipsychotics), D2, uye serotonin receptor (inonzi atypical antipsychotics), 5-HT2A.2; nepo xanomeline iri acetylcholine muscarinic receptor agonist yeM1 uye M4 subtypes.3 uye trospium chloride ndeye acetylcholine muscarinic receptor antagonist yeM1, M2 uye M3 subtypes.4. Saka iyi ndiyo nzira itsva yekurapa schizophrenia uye inojekesa mukana wekuti panogona kunge paine mamwe asina kushandiswa emishonga emishonga anogona kusanganisira kunanga acetylcholine muscarinic receptors yekurapa schizophrenia kana psychosis zvachose.
schizophrenia chirwere chepfungwa chinoratidzwa nezviratidzo zvepfungwa zvakadai sekunyengedza, kuona uye kushaya kwekukurudzira. Izvi zvinorongedzerwa kudzorwa zvakanyanya kuburikidza neiyo dopaminergic system uye zvinogona zvinosanganisirawo serotonergic system.5. Zvisinei, acetylcholine muscarinic receptors inozivikanwa kuti inopindirana zvakasimba ne dopamine neurons inokonzera kusunungurwa kwavo kwe dopamine mu neuronal synapses uye postsynaptic madhara.6. Kuburikidza nenzira iyi iyo yekutanga antipsychotic, clozapine, iyo inopesana ne serotonin uye dopamine receptors, inofungidzirwa kuti ine yakanaka side effect profile yakasiyana nemamwe antipsychotics nekuda kwekupokana kwayo kweM1 acetylcholine receptors.5.
Miedzo mitatu yekiriniki yakadzorwa neplacebo yakashandisa musanganiswa wezvinodhaka semonotherapy pakurapa schizophrenia varwere vaive nekuwedzera kwakanyanya kwepsychosis, nemiedzo yakatora mavhiki mashanu.7. Musanganiswa wezvinodhaka wakanyanya kudarika placebo mukurapa schizophrenic zviratidzo sekuyerwa nePANSS (Positive uye Negative Syndrome Scale) mumakiriniki ekuyedzwa, kunyanya nezvezviratidzo zvisina kunaka sekushaikwa kwekukurudzira uye kushomeka kwekutaura, zvichiratidza kuti inobudirira antipsychotic kurapa.7.
Izvo zvakaratidzwa nekiriniki mabhenefiti ekunangisa iyo cholinergic system yekurapa schizophrenia uye psychosis inoratidza kugona kwemishonga mitsva yezvirwere zvepfungwa izvi zvingave zvechimiro chakanaka chemhedzisiro kana zvichienzaniswa neyakajairika antipsychotics.
***
References
- FDA Nhau kuburitswa - FDA Inobvumidza Mushonga neNew Mechanism Yekuita Yekurapwa kweSchizophrenia. Yakabudiswa 26 September 2024. Inowanikwa pa https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-schizophrenia
- Chokhawala K, Stevens L. Antipsychotic Mishonga. [Yakagadziridzwa 2023 Kukadzi 26]. Mu: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Inowanikwa kubva: https://www.ncbi.nlm.nih.gov/books/NBK519503/
- Xanomeline. Sayenzi Yakananga. Inowanikwa pa https://www.sciencedirect.com/topics/neuroscience/xanomeline
- Rovner, ES Trospium Chloride muKutarisira kweKunyanya Kushanda Bladder. Zvinodhaka 64, 2433-2446 (2004). https://doi.org/10.2165/00003495-200464210-00005
- McCutcheon, Robert A. et al. Schizophrenia, Dopamine uye Striatum: Kubva kuBiology kusvika kuZviratidzo. Maitiro muNeuroscience, Vhoriyamu 42, Chinyorwa 3, 205 - 220. DOI: DOI: https://doi.org/10.1016/j.tins.2018.12.004
- Threlfell1 S. uye Cragg SJ, 2011. Dopamine inoratidzira mudorsal versus ventral striatum: basa rinoita recholinergic interneurons. Mberi. Syst. Neurosci., 03 Kurume 2011. Vhoriyamu 5 - 2011. DOI: https://doi.org/10.3389/fnsys.2011.00011
- Horan WP, and said 2024. Kubudirira kweKarXT pazviratidzo zvisina kunaka mu acute schizophrenia: A post hoc kuongororwa kwe data yakabatanidzwa kubva ku3 miedzo. Schizophrenia Research. Vhoriyamu 274, Zvita 2024, Mapeji 57-65. DOI: https://doi.org/10.1016/j.schres.2024.08.001
***